PhRMA Weighs In On European Consumer Drug Information Proposal
Executive Summary
Supporting a proposed European policy change permitting manufacturers to provide more drug information to the public, the Pharmaceutical Research and Manufacturers of America suggests that permissible information could include ongoing clinical research and disease management data not contained in approved product summaries
You may also be interested in...
EC Seeks To Provide More Drug Information But Not Through DTC Ads
The European Commission intends to propose regulatory changes aimed at ensuring that patients have greater access to non-biased information on medications
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.